Johnson & Johnson (NYSE:JNJ) Stock Position Boosted by Biltmore Family Office LLC

Key Points

• Biltmore Family Office LLC increased its holdings in Johnson & Johnson by 15.6% during the 1st quarter, owning 19,873 shares valued at approximately $3.3 million.
• Analysts have mixed ratings for Johnson & Johnson, with ten analysts$174.50.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, resulting in a yield of 3.0% and a payout ratio of 55.61%.

Biltmore Family Office LLC lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,873 shares of the company's stock after buying an additional 2,683 shares during the period. Biltmore Family Office LLC's holdings in Johnson & Johnson were worth $3,296,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Lantz Financial LLC increased its stake in shares of Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares during the period. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $453,000. Joel Isaacson & Co. LLC grew its holdings in shares of Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares in the last quarter. State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC grew its holdings in shares of Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.4%

NYSE JNJ traded up $0.65 during trading hours on Monday, reaching $173.98. 7,208,197 shares of the company traded hands, compared to its average volume of 9,486,962. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $174.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $418.99 billion, a PE ratio of 18.61, a PEG ratio of 2.21 and a beta of 0.41. The company has a 50 day moving average of $159.26 and a two-hundred day moving average of $157.60.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company earned $2.82 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JNJ. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Guggenheim reaffirmed a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, UBS Group increased their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.